cardiovascular%20disease%20prevention
CARDIOVASCULAR DISEASE PREVENTION
Patients 18 years old and above should receive a risk factor assessment for cardiovascular disease (CVD) at every routine physician visit.
Cardiovascular disease development is closely related to lifestyle characteristics and associated risk factors.
There is an overwhelming scientific evidence that lifestyle modifications and reduction of risk factors can slow the development of CVD both before and after the occurrence of a cardiovascular event.
Primary CVD prevention is aimed at the healthy population, individuals who have several CV risk factors or 1 CV risk factor at a very high level, and individuals whose risk for a CV event is high. Secondary CVD prevention is aimed at individuals with confirmed CVD.
  1. American Diabetes Association. Standards of medical care in diabetes - 2013. Diabetes Care. 2013 Jan;36(Suppl 1):S11-S66. doi: 10.2337/dc13-S011. Accessed 02 Aug 2013. PMID: 23264422
  2. British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005 Dec;91(Suppl 5):v1-v52. PMID: 16365341
  3. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007 Jan;30(1):162-172. PMID: 17192355
  4. Jellinger PS, Smith DA, Mehta AE, et al; AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis. American Association of Clinical Endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract. 2012 Mar;18(Suppl 1):1-78. https://www.ncbi.nlm.nih.gov. Accessed 4 Sep 2013. PMID: 22522068
  5. Corrales-Medina VF, Suh KN, Rose G, et al. Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLoS Med. 2011 Jun 28 Jun 2011;8(6):e1001048. doi: 10.1371/journal.pmed.1001048. Accessed 28 Jun 2011. PMID: 21738449
  6. Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis. 2007 Jul;45(2):158-165. PMID: 17578773
  7. Lackland DT, Elkind MS, D'Agostino R Sr, et al; American Heart Association Stroke Council; Council on Epidemiology and Prevention; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Council on Peripheral Vascular Dise. Inclusion of stroke in cardiovascular risk prediction instruments: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012 Jul;43(7):1998-2027. PMID: 22627990
  8. O'Keefe JH, Carter MD, Lavie CJ. Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach. Mayo Clin Proc. 2009 Aug;84(8):741-757. PMID: 19648392
  9. Perk J, De Backer G, Gohlke H, et al; European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012 Jul;33(13):1635-1701. PMID: 22555213
  10. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002 Jul;160(3):388-391. PMID: 12119259
  11. Redberg RF, Benjamin EJ, Bittner V, et al; American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; Preventive Cardiovascular Nurses Association. AHA/ACCF [corrected] 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on performance measures (writing committee to develop performance measures for primary prevention of cardiovascular disease): developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association: endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women's Health Research. Circulation. 2009 Sep;120(13):1296-1336. doi: 10.1161/CIRCULATIONAHA.109.192617. PMID: 19770388
  12. Smith SC, Benjamin EJ, Bonow RO, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011 Nov;124(22):2458-2473. PMID: 22052934
  13. Siriwardena AN, Gwini SM, Coupland CA. Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: matched case-control study. CMAJ. 2010 Oct;182(15):1617-1623. doi: 10.1503/cmaj.091819. PMID: 20855479
  14. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009 Mar;150(6):396-404. PMID: 19293072
  15. Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J. 1998 Oct;19(10):1434-1503. PMID: 9820987
  16. International Task Force for Prevention of Coronary Heart Disease & International Atherosclerosis Society. Pocket guide to prevention of coronary heart disease. Germany; 2003 Jan:001-128
  17. Medical Services Commission. Cardiovascular disease - primary prevention. Toronto (ON); 2008 Mar:001-018.
  18. MedWormhttp://www.medworm.com/rss/index.php/Cardiology/7/http://www.medworm.com/rss/medicalfeeds/specialities/Cardiology.xml
  19. Noncommunicable Diseases and Mental Health, World Health Organization. Integrated management of cardiovascular risk. Report of WHO meeting, Geneva. http://whqlibdoc.who.int/. Jul 2012.
  20. Scottish Intercollegiate Guidelines Network. Management of obesity. SIGN. http://www.sign.ac.uk. Feb 2010. Accessed 02 Aug 2013.
  21. World Health Organization. Prevention of cardiovascular disease: guidelines for assessment and management of cardiovascular risk. WHO. http://whqlibdoc.who.int/. 2007.
  22. New Zealand Guidelines Group, National Heart Foundation of New Zealand & Stroke Foundation of New Zealand. The assessment and management of cardiovascular risk. http://www.health.govt.nz/. Dec 2003.
  23. Ministry of Health Singapore. Screening for cardiovascular disease and risk factors. MOH (Singapore). http://www.moh.gov.sg/. 2011.
  24. Ministry of Health Malaysia. Prevention of cardiovascular disease in women. http://www.acadmed.org.my. 2008.
  25. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun;129(25)(Suppl 2):S49-S73. doi: 10.1161/01.cir.0000437741.48606.98. PMID: 24222018
  26. Jensen MD, Ryan DH, Apovian CM, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Nov 12, 2013. J Am Coll Cardiol. 2014 Jul;63(Suppl 25 Pt B):2985-3023. doi: 10.1016/j.jacc.2013.11.004. PMID: 24239920
  27. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Nov 12, 2013. Circulation. 2014 Jun;129(25)(Suppl 2):S1-S45. doi: 10.1161/01.cir.0000437738.63853.7a. PMID: 24222016
  28. Piepoli MF, Hoes AW, Agewall S, et al; Authors/Task Force Members. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). May 23, 2016. Eur Heart J. 2016 May. doi: 10.1093/eurheartj/ehw106. Accessed 29 Jun 2016. PMID: 27222591
  29. Ministry of Health Malaysia. Prevention of cardiovascular disease in women 2016. 2nd ed. Ministry of Health Malaysia Web Site. http://www.moh.gov.my. 2016. Accessed 21 Mar 2017.
  30. Anderson TJ, Grégoire J, Pearson GJ, et al. 2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2016 Nov;32(11):1263-1282. doi: 10.1016/j.cjca.2016.07.510. PMID: 27712954
  31. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract. 2017 Feb. doi: 10.4158/EP171764.GL. PMID: 28156151
  32. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on clinical expert consensus documents. J Am Coll Cardiol. 2016 Jul;68(1):92-125. doi: 10.1016/j.jacc.2016.03.519. PMID: 27046161
  33. Siscovick DS, Barringer TA, Fretts AM, et al; American Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Omega-3 polyunsaturated fatty acid (Fish Oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. Circulation. 2017 Mar. doi: 10.1161/CIR.0000000000000482. PMID: 28289069
  34. St-Onge MP, Ard J, Baskin ML, et al; American Heart Association Obesity Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council. Meal timing and frequency: implications for cardiovascular disease prevention: a scientific statement from the American Heart Association. Circulation. 2017 Feb;135(9):e96-e121. doi: 10.1161/CIR.0000000000000476. PMID: 28137935
  35. Cheung BM, Cheng CH, Lau CP, et al. 2016 Consensus statement on prevention of atherosclerotic cardiovascular disease in the Hong Kong population. Hong Kong Med J. 2017 Apr;23(2):191-201. doi: 10.12809/hkmj165045. Accessed 01 Aug 2017. PMID: 28387202
  36. Dehghan M, Mente A, Zhang X, et al; Prospective Urban Rural Epidemiology (PURE) study investigators. Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. Lancet. 2017 Aug 28:pii: S0140-6736(17)32252-3. doi: 10.1016/S0140-6736(17)32252-3. Accessed 07 Sep 2017. PMID: 28864332
  37. Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015 Jun 24;11:967-977. doi: 10.2147/TCRM.S84210. PMID: 26150723
  38. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017 Nov 7:pii: S0735-1097(17)41519-1. doi: 10.1016/j.jacc.2017.11.006. Accessed 16 Nov 2017. PMID: 29146535
  39. Ministry of Health Malaysia, Academy of Medicine Malaysia and National Heart Association of Malaysia. Clinical practice guidelines on primary & secondary prevention of cardiovascular disease 2017. Academy of Medicine Malaysia. http://www.acadmed.org.my. 2017.
  40. Stewart J, Manmathan G, Wilkinson P. Primary prevention of cardiovascular disease: a review of contemporary guidance and literature. JRSM Cardiovasc Dis. 2017;6:1-9. doi: 10.1177/2048004016687211. PMID: 28286646
  41. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 Nov 3. pii: S0735-1097(18)39033-8. doi: 10.1016/j.jacc.2018.11.002. Accessed 29 Jan 2019. PMID: 30423391
  42. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation. 2019 Mar 17;CIR0000000000000678. doi: 10.1161/CIR.0000000000000678. (Epub ahead of print). PMID: 30879355
  43. Das SR, Everett BM, Birtcher KK et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2018 Dec 18;72(24):3200-3223. doi: 10.1016/j.jacc.2018.09.020. PMID: 30497881
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
11 Apr 2018
Survivors of Hodgkin’s lymphoma are at greater risk of developing subsequent malignant neoplasm (SMN) and cardiovascular disease (CVD), according to a study.